SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.83), $0.14 worse than the analyst estimate of ($1.69). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.01 million.

• Announced positive topline data from pivotal WATERFALL Study of zuranolone in patients with MDD showing statistically significant and clinically meaningful reduction in depressive symptoms at Day 15, primary endpoint
• Continued pipeline expansion and acceleration advancing all three brain health franchises, including first patient dosed in SAGE-718 PARADIGM Parkinson’s disease Study Part B and initiation of Phase 1 program for SAGE-689
• Updated enrollment guidance for Phase 3 SKYLARK Study of zuranolone in women with PPD with topline data now expected mid-2022
• Company announces REDWOOD and RAINFOREST Studies not expected to be required for a potential zuranolone NDA submission

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.